News | August 02, 2021
Glenmark signs agreement with SaNOtize to manufacture NONS
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
The first batch will be shipped to the Gamaleya Center for the quality control
TLD is recommended by WHO, USAID, and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
